Table 3.
Antitumor activity of pembrolizumab in patients with advanced head and neck squamous cell carcinoma (Asia‐Pacific all‐patients‐as‐treated population)
| Response evaluation | Responses per RECIST version 1.1 by central imaging vendor review | Responses per RECIST version 1.1 by investigator assessment | ||||
|---|---|---|---|---|---|---|
| All patients, n = 26 | Progressed following prior platinum treatment, n = 24 | All patients, n = 26 | ||||
| n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | |
| ORR | 5 | 19 (7‐39) | 4 | 17 (5‐37) | 6 | 23 (9‐44) |
| CR | 0 | 0 (0‐0) | 0 | 0 (0‐0) | 0 | 0 (0‐0) |
| PR | 5 | 19 (7‐39) | 4 | 17 (5‐37) | 6 | 23 (9‐44) |
| SD | 8 | 31 (14‐52) | 8 | 33 (16‐55) | 9 | 35 (17‐56) |
| PD | 12 | 46 (27‐67) | 11 | 46 (26‐67) | 10 | 39 (20‐59) |
| NAa | 1 | 4 (<1‐20) | 1 | 4 (<1‐21) | 1 | 4 (<1‐20) |
CI, confidence interval; CR, complete response; NA, not assessed; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.
a
Patient had no postbaseline imaging.